Cytokinetics To Present Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference

Main Category: Public Health
Also Included In: Clinical Trials / Drug Trials;  Conferences
Article Date: 01 Dec 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that a poster and oral presentation summarizing non-clinical data regarding CK-2017357, a fast skeletal troponin activator, are scheduled to be presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 at the Princesa Sofia Hotel in Barcelona, Spain.

In June 2009, Cytokinetics announced that it had initiated a first-time-in-humans Phase I clinical trial of CK-2017357 in healthy male volunteers. The first part, or "Part A," of this trial is designed to assess the safety, tolerability, and pharmacokinetic profile of this drug candidate and to determine its maximum tolerated dose and plasma concentration, and is on-going. In November 2009, Cytokinetics announced that the company had initiated the second part, or "Part B," of this clinical trial. Part B is designed to evaluate the pharmacodynamic effect of single doses that have been tolerated to date in Part A of this trial. In November 2009, the company also announced the initiation of a second Phase I clinical trial to investigate the safety, tolerability and pharmacokinetic profile of CK-2017357 after multiple oral doses to steady state in healthy male volunteers.

CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate from the company's skeletal sarcomere activator program. CK-2017357 selectively activates the fast skeletal troponin complex and increases its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated encouraging pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction.

Oral Presentation

Session #14: "Direct Activation of the Skeletal Sarcomere by the Troponin Activator, CK-2017357, a Novel Approach to Improving Skeletal Muscle Function" is scheduled to be presented in the I-Clinical Track - Clinical Trials: Late Breaking Approaches, on Monday, December 7, from 11:00 AM - 11:30 AM Central European Time. The presentation will be made by Fady Malik, MD, PhD, FACC, Vice President, Biology and Therapeutics, Cytokinetics, Inc., South San Francisco, California.

Poster Presentation

The abstract titled, "The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force in-vitro and in-situ" is scheduled to be displayed as a poster presentation on December 6, 2009 - December 7, 2009 during the Poster Sessions.

Source
Cytokinetics

• Additional
• References
• Citations